Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Start Date

<< Previous

Bullboard Posts

Next >>

Comment by Duster340on Jan 19, 2024 10:37am

136 Views

Post# 35835797

RE:RE:RE:RE:Start Date

Inthepez wrote:
Poor dumpster, it was dead money since AME...less than 2 months for p2 initiation isn't dead money, in comparison. You've been wrong in your analysis too many times to count.

like clockwork though, you spread fear when you want to shake the tree and hype when you are back in. At least you're entertaining like a monkey banging drums

poor pez, ate once again is going to make you hold the bag, you have got to learn when to buy when to sell, this stock is easy to read, i have been playing it like a fiddle for years. you should have clued in, better luck next time lol

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario